drugset / Trial / NCT02618629

Mass Balance and Metabolism Study of 14C-Z-215

NCT02618629

Phase 1 Completed 6 enrolled Zeria Pharmaceutical
NaSingle-groupOpen-labelBasic science

Summary

The aim of this Phase I study is to determine the absorption, metabolism, and excretion of 14C-Z-215 in healthy male subjects following a single oral administration at a therapeutically relevant dose level (20 mg).

Timeline

Start
2016-01
Primary completion
2016-06
Completion
2016-09

Drugs

EvaluationDrugModalityDoseRoute
Subject AZELOPRAZOLE Small molecule 20 mg Oral

Indications

No indication recorded.